Thermo Fisher Scientific Baltics UAB, part of Thermo Fisher Scientific, Inc., is a Lithuanian company located in Vilnius that operates as a biotechnology company that develops and manufactures products for global markets life science research and diagnostics.

Stratagene California is an American biotechnological company based in La Jolla, California, a maker of life science research and diagnostic products. It was established in 1984 and incorporated in California. It has been involved with the fields of cellular analysis, cloning, cytogenomics, DNA methylation and DNA Sizing and Quantification and food testing. In 2007, Agilent Technologies acquired Stratagene for $250 million, spinning off certain business assets and licensing certain molecular diagnostics technology to a new entity, Decisive Diagnostics. As of October 2011, the Chief Executive of the new company is Joseph Sorge, original founder and CEO of Stratagene.

iNtRON Biotechnology, Inc. engages in the development of super-bacteria treatment, antibiotics alternatives, bio new drug, molecular diagnostics and artificial blood. Its products include anti-bacterial agents, identification kits, research reagents and kits. The company was founded on January 18, 1999 and is headquartered in Seongnam-si, South Korea.

Direct Genomics is making genomics an affordable part of everyday patient care. The company’s GenoCare instrument is the first single molecule sequencing system for clinical use. That simplifies sequencing by directly reading individual DNA and RNA molecule information from customer’s blood or tissue samples, delivering significant improvements in cost and speed. Established in 2012, Direct Genomics is headquartered in Shenzhen, China and backed by institutional and private investors.

Novogene is a leading provider of genomic services and solutions with cutting edge NGS and bioinformatics expertise and the largest sequencing capacity in the world. Novogene utilizes scientific excellence, a commitment to customer service and unsurpassed data quality to help their clients realize their research goals in the rapidly evolving world of genomics. The company has become a world-leader in NGS services, with 1,800 employees and multiple locations across the globe. Novogene’s depth of experience has resulted in the ownership of 49 NGS-related patents, as well as the publishing of over 1850 customer research papers, often in well-respected publications such as Nature and Science. Company founder, Dr. Ruiqiang Li, is widely recognized as one of the world’s leading experts in genomics and bioinformatics, owning 12 patents and authoring over 90 peer-reviewed publications that have been cited >15,000 times. Best known for developing the software SOAP (Short Oligonucleotide Analysis Package) for ultra-fast sequence mapping, variation detection, and de novo genome assembly, Dr. Li has focused Novogene’s services on performing sequencing AND providing informatics to fully empower and enable their customers to move forward rapidly and effectively in their scientific endeavors.

Daiichi Seiyaku Co., Ltd. engaged in the manufacture, sale research and development of medicine. The company was founded on October 1, 1915 and was headquartered in Tokyo, Japan.

TransGen Biotech was formed to develop new and cost-effective life science research products. It now produces more than 200 reagents for molecular and cellular biology. PCR/qPCR/RT-PCR polymerases and supermixes, DNA markers, high-efficiency chemically competent cells, 5-minute cloning, and expression vectors, nucleic acid extraction and purification kits, cell culture and detection, next-generation sequencing, and stem cells are among the products in their portfolio.

Amoy Diagnostics is a research and development based diagnostic company focusing on molecular diagnostics for oncology precision medicine. AmoyDx has a portfolio of molecular diagnostic assays. Based on multiple technology platforms including PCR, NGS, FISH and IHC, AmoyDx's core product categories include single gene testing kits, multi-gene testing panels, NGS panels, and NGS analytical systems.

BGI Genomics Co., Ltd. is a holding company that engages in development of science and technology services in genomics field. Its business scope ranges from scientific, health, agricultural and informatics. The company was founded by Wang Jian on September 9, 1999 and is headquartered in Shenzhen, China.

Jiangsu Kangwei Century Biotechnology Co., Ltd., established on 2010-09-03, Business scope includes research and development of biological reagents,Sales(Free of Hazardous Chemicals,Does not contain drugs)and technical services;one type,Class II,Research and development of three types of medical devices,Production,Sales;Equipment research and development,Sales;Kits for Nucleic Acid Extraction for Scientific Research,PCRAmplification Kit,Production of kits for protein analysis and detection;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that are restricted by the state to be operated by enterprises or prohibited from import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments) licensed items:Disinfectant production(Free of Hazardous Chemicals)(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,Specific business projects are subject to approval results) General project:Disinfectant sales(Free of Hazardous Chemicals)(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)

Tianjin Huada Medical Laboratory Co., Ltd., established on 2014-10-09, Business scope includes licensed projects:medical service;Class III medical device business.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments).General project:Medical Research and Experimental Development;Import and export;Technology Import and Export;Import and export agency;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Experimental analysis instrument sales;Specialty Chemicals Sales(Free of Hazardous Chemicals);Retailing of computer software, hardware and auxiliary equipment;Sales of Class II Medical Devices;housing lease;Non-residential real estate leases.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).

Guangzhou Huada Gene Medical Laboratory Co., Ltd., established on 2014-01-27, Business scope includes sales of Class I medical devices;Chemical product sales(No licensed chemical products);Medical Research and Experimental Development;Specialty Chemicals Sales(Free of Hazardous Chemicals);Office Equipment Sales;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Experimental analysis instrument sales;Instrument sales;Retailing of computer software, hardware and auxiliary equipment;Wholesale of computer software, hardware and auxiliary equipment;Office equipment rental service;Medical equipment rental;Non-residential real estate leases;Sales of Class II Medical Devices;Sales of hygiene products and single-use medical products;Domestic trade agent;Technology Import and Export;Import and export agency;Import and export;Class III medical device business;medical service;

CEA is a French government-funded technological research organisation. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world. The CEA is the French Alternative Energies and Atomic Energy Commission (Commissariat à l'énergie atomique et aux énergies alternatives). It is a public body established in October 1945 by General de Gaulle. A leader in research, development and innovation, the CEA mission statement has two main objectives: To become the leading technological research organization in Europe and to ensure that the nuclear deterrent remains effective in the future. The CEA is active in four main areas: low-carbon energies, defense and security, information technologies and health technologies. In each of these fields, the CEA maintains a cross-disciplinary culture of engineers and researchers, building on the synergies between fundamental and technological research. The total CEA workforce consisted of 15 838 employees. Across the whole of the CEA (including both civilian and military research), there were 1556 PhD students and 293 post-docs. The CEA is based in ten research centers in France, each specializing in specific fields. The laboratories are located in the Paris region, the Rhône-Alpes, the Rhône valley, the Provence-Alpes-Côte d'Azur region, Aquitaine, Central France and Burgundy. The CEA benefits from the strong regional identities of these laboratories and the partnerships forged with other research centers, local authorities and universities.

BGI Shenzhen Co., Ltd. engages in the equity investment and asset management. Its business scope includes research and development and sales of computer hardware and software and peripheral equipment technology; import and export of goods and technology; equity investment; investment in industrial development; and aquatic product farming and sales. The company was founded on August 21, 2008 and is headquartered in Shenzhen, China.

American Cyanamid Company was a U.S.-based diversified company with businesses in several fields. The company was a manufacturer of agricultural chemicals, cosmetics, perfumes, building products, plastics and pharmaceuticals. The company was listed as a top 100 manufacturing company by Fortune magazine in the 1970s. Cyanamid was founded in 1907 and employed over 100,000 people around the world by 2000. The company maintained a monopoly over tetracycline, an antibiotic used against bacterial infections. A theft of the organism led to the loss of the monopoly as rival companies were able to produce generic versions of the formula, leading to huge losses to the company. The company sold most of its businesses in the early 2000s and is now operated under the name Cytec.  

Matsushita Electronics Corp. develops and manufactures electronic products. Its products include plasma TVs, DVD players, and digital cameras. It is a subsidiary of Matsushita Electric Industrial Co. Ltd. The company is headquartered in Osaka, Japan.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Agilent Technologies, Inc. engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level. The Diagnostics and Genomics segment consists of activity providing active pharmaceutical ingredients for oligo-based therapeutics, as well as solutions that include reagents, instruments, software and consumables. The Agilent CrossLab segment includes startup, operational, training and compliance support, software as a service, and asset management and consultative services. The company was founded in May 1999 and is headquartered in Santa Clara, CA.